FDA Approves First Cancer Biosimilar: Amgen’s Mvasi

Drug Industry Daily
A A
The FDA approved the first U.S. biosimilar for the treatment of cancer, Amgen’s Mvasi, a biosimilar of the blockbuster Avastin.

To View This Article:

Login

Subscribe To Drug Industry Daily